Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 8.4% – Should You Buy?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s share price traded up 8.4% on Thursday . The stock traded as high as $21.78 and last traded at $21.86. Approximately 857,197 shares changed hands during trading, a decline of 62% from the average daily volume of 2,268,250 shares. The stock had previously closed at $20.16.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ADPT. Morgan Stanley increased their target price on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. BTIG Research restated a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Finally, Guggenheim lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $20.83.

Adaptive Biotechnologies Trading Up 8.0%

The stock’s 50 day moving average is $16.50 and its two-hundred day moving average is $15.96. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of -66.20 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.20) EPS. On average, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Francis Lo sold 44,838 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $22.59, for a total transaction of $1,012,890.42. Following the completion of the transaction, the insider directly owned 230,713 shares of the company’s stock, valued at $5,211,806.67. This trade represents a 16.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the completion of the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 977,725 shares of company stock worth $19,352,587 in the last 90 days. 5.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ADPT. 1492 Capital Management LLC bought a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $1,484,000. Jupiter Asset Management Ltd. raised its holdings in shares of Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after purchasing an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB lifted its stake in Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock valued at $9,825,000 after purchasing an additional 110,000 shares during the last quarter. UBS Group AG lifted its stake in Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after purchasing an additional 257,947 shares during the last quarter. Finally, Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.